---
title: "比利时的 Agomab Therapeutics 在美国首次公开募股中筹集了 2 亿美元"
description: "Agomab Therapeutics 周四表示，该公司在美国首次公开募股中筹集了 2 亿美元，为这家生物制药公司的纳斯达克上市奠定了基础"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275051300.md"
published_at: "2026-02-06T00:30:18.000Z"
---

# 比利时的 Agomab Therapeutics 在美国首次公开募股中筹集了 2 亿美元

> Agomab Therapeutics 周四表示，该公司在美国首次公开募股中筹集了 2 亿美元，为这家生物制药公司的纳斯达克上市奠定了基础

Agomab Therapeutics 宣布已在美国首次公开募股中筹集了 2 亿美元，为这家生物制药公司的纳斯达克首秀奠定了基础。

### Related Stocks

- [PBE.US - 动态生物技术与基因组 ETF - Invesco](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [XBI.US - 标普生物技术 ETF - SPDR](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [SBIO.US - 医药突破 ETF - ALPS](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [IBB.US - 纳斯达克生物科技指数 ETF - iShares Nasdaq](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [BIB.US - 2 倍做多纳斯达克生物技术 ETF - ProShares](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [APGE.US - Apogee Therapeutic](https://longbridge.com/zh-CN/quote/APGE.US.md)
- [FBT.US - 纽交所高增长板生物技术指数 ETF - First Trust](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/zh-CN/quote/IBBQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Apogee Therapeutics CEO Sells 20,000 Shares | Michael Thomas Henderson, CEO of Apogee Therapeutics, sold 20,000 shares of common stock on February 11, 2026, under a R | [Link](https://longbridge.com/zh-CN/news/275958084.md) |
| Key facts: Candel Therapeutics secures $100M funding; plans drug launches | Candel Therapeutics has secured a $100 million funding deal with RTW Investments for its therapy Aglatimagene Besadenove | [Link](https://longbridge.com/zh-CN/news/276481541.md) |
| Halozyme 2025 revenue up 38%, Q4 EPS misses estimates | Halozyme's 2025 revenue increased by 38% to $1.4 billion, primarily due to growth in ENHANZE products. However, Q4 adjus | [Link](https://longbridge.com/zh-CN/news/276168085.md) |
| Janux commences participant dosing in Phase I JANX011 trial | Janux Therapeutics has initiated participant dosing in a Phase I clinical trial for JANX011, a CD19-targeted bispecific  | [Link](https://longbridge.com/zh-CN/news/276216344.md) |
| Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission | Allogene Therapeutics (NASDAQ:ALLO) anticipates releasing initial data in April from its ALPHA3 study, which evaluates i | [Link](https://longbridge.com/zh-CN/news/276286748.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。